Literature DB >> 31525648

Immune checkpoint blockade in small cell lung cancer.

Rebecca Y Tay1, David Heigener2, Martin Reck3, Raffaele Califano4.   

Abstract

Despite the highly immunogenic potential of small cell lung cancer (SCLC), progress in evaluating the therapeutic value of immune checkpoint agents has lagged behind that of non-small cell lung cancer. Results from a number of phase I-III clinical trials that specifically address the use of anti-PD-1, anti-PD-L1 and anti-CTLA-4 agents in SCLC have now been reported. This review will focus on the available evidence for immune checkpoint blockade in SCLC and review current biomarker strategies with the aim of providing perspective and interpretation of this data for clinical practice.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atezolizumab; Immunotherapy; Ipilimumab; Nivolumab; Pembrolizumab; Small cell lung cancer

Year:  2019        PMID： 31525648     DOI： 10.1016/j.lungcan.2019.08.024

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  6 in total

1.  Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.

Authors:  Nan Geng; Cui-Min Ding; Zhi-Kun Liu; Shan Song; Wen-Xia Hu
Journal:  Int J Clin Oncol       Date:  2021-01-03       Impact factor: 3.402

2.  Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer.

Authors:  Shuyue Jiao; Xin Zhang; Dapeng Wang; Hongyong Fu; Qingxin Xia
Journal:  Cancer Manag Res       Date:  2022-04-19       Impact factor: 3.602

Review 3.  The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.

Authors:  Jingjie Chen; Shengnan Li; Qigu Yao; Nannan Du; Xiaojun Fu; Yuanmei Lou; Mengru Wang; Feiyan Mao; Danyi Mao; Parikshit Asutosh Khadaroo; Yingying Tang
Journal:  World J Surg Oncol       Date:  2020-07-03       Impact factor: 2.754

4.  Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.

Authors:  Li-Na He; Xuanye Zhang; Haifeng Li; Tao Chen; Chen Chen; Yixin Zhou; Zuan Lin; Wei Du; Wenfeng Fang; Yunpeng Yang; Yan Huang; Hongyun Zhao; Shaodong Hong; Li Zhang
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

5.  Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: A case report.

Authors:  Mattia Sirgiovanni; Clemens Hinterleitner; Marius Horger; Naushad Bijoy Atique; Ulrich M Lauer; Lars Zender; Martina Hinterleitner
Journal:  Thorac Cancer       Date:  2021-01-17       Impact factor: 3.500

6.  The clinical significance of integrin subunit alpha V in cancers: from small cell lung carcinoma to pan-cancer.

Authors:  Yu-Lu Tang; Guo-Sheng Li; Dong-Ming Li; Deng Tang; Jie-Zhuang Huang; Hao Feng; Rong-Quan He; Zhi-Guang Huang; Yi-Wu Dang; Jin-Liang Kong; Ting-Qing Gan; Hua-Fu Zhou; Jing-Jing Zeng; Gang Chen
Journal:  BMC Pulm Med       Date:  2022-08-04       Impact factor: 3.320
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.